BMED Long Call Strategy
BMED (iShares Health Innovation Active ETF), in the Financial Services sector, (Asset Management industry), listed on AMEX.
BMED focuses on total return by investing in the broad health sciences group of industries from R&D to production and distribution of medical supplies in different fields, including dental, optical or pharmaceuticals. It also involves healthcare providers including health facilities and hospitals or those providing related administrative, management or financial support. The fund reaches into non-human health (e.g., survival of plants and animals) such as firms that increase crop yields, taste, nutritional content or improve pet health. BMED will include firms with varying market-cap with bias to small- and mid-caps that may include foreign non-USD-denominated securities. The fund may also hold REITs that own hospitals and IPOs. During temporary defensive periods, the fund may invest up to 100% of assets in liquid, short-term investments and can enter in credit default swaps for risk management.
BMED (iShares Health Innovation Active ETF) trades in the Financial Services sector, specifically Asset Management, with a market capitalization of approximately $14.5M, a beta of 0.68 versus the broader market, a 52-week range of 27.25-37.4, average daily share volume of 3K, a public-listing history dating back to 2020, approximately 79 full-time employees. These structural characteristics shape how BMED etf options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.68 indicates BMED has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. BMED pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long call on BMED?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
BMED snapshot
As of November 13, 2026, spot at $35.90. The long call on BMED below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long call structure on BMED specifically: IV rank is unavailable in the current snapshot, so regime-based timing for BMED is inferred from ATM IV alone. The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BMED expiries trade a higher absolute premium for lower per-day decay. Position sizing on BMED should anchor to the underlying notional of $35.90 per share and to the trader's directional view on BMED etf.
BMED long call setup
The BMED long call below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BMED at $35.90 on that close, the first option leg uses a $36.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BMED chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BMED shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $36.00 | $1.63 |
BMED long call risk and reward
- Net Premium / Debit
- -$163.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$163.00
- Breakeven(s)
- $37.63
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
BMED long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on BMED. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$163.00 |
| $7.95 | -77.9% | -$163.00 |
| $15.88 | -55.8% | -$163.00 |
| $23.82 | -33.6% | -$163.00 |
| $31.76 | -11.5% | -$163.00 |
| $39.69 | +10.6% | +$206.29 |
| $47.63 | +32.7% | +$999.95 |
| $55.57 | +54.8% | +$1,793.61 |
| $63.50 | +76.9% | +$2,587.27 |
| $71.44 | +99.0% | +$3,380.92 |
When traders use long call on BMED
Long calls on BMED express a bullish thesis with defined risk; traders use them ahead of BMED catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
BMED thesis for this long call
A BMED long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. As a Financial Services name, BMED options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BMED-specific events.
BMED long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BMED positions also carry Financial Services sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BMED alongside the broader basket even when BMED-specific fundamentals are unchanged. Long-premium structures like a long call on BMED are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current BMED chain quotes before placing a trade.
Frequently asked questions
- What is a long call on BMED?
- A long call on BMED is the long call strategy applied to BMED (etf). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With BMED etf at $35.90 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed BMED chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are BMED long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the BMED long call priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV the current ATM IV), the computed maximum profit is unbounded per contract and the computed maximum loss is -$163.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BMED long call?
- The breakeven for the BMED long call priced on this page is roughly $37.63 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk.
- When should you consider a long call on BMED?
- Long calls on BMED express a bullish thesis with defined risk; traders use them ahead of BMED catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current BMED implied volatility affect this long call?
- Current BMED ATM IV is the current ATM IV; IV rank context is unavailable in the current snapshot.